Refine by
Medical Officer Articles & Analysis
390 news found
Their support is instrumental to making this improved access a reality,” said Philippe Menu, M.D., Ph.D, Chief Medical and Chief Product Officer, SOPHiA GENETICS. “Additionally, the breadth and depth of real-world data that we will generate through the implementation of this decentralized liquid biopsy testing platform on a global scale will be ...
We are very excited at the prospect of contributing to meaningful clinical advances for patients with ecDNA-driven oncogene amplified cancers,” said Philippe Menu, M.D., PhD., Chief Medical Officer and Chief Product Officer, SOPHiA GENETICS. SOPHiA GENETICS provides a technology-agnostic cloud-native platform for the computing, ...
FOLR1 testing is recommended for patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.1 “Expanding our offerings to include tests for specific, predictive biomarkers, like HER2, can help reveal a patient’s responsiveness to therapies that have the potential to positively impact their outcome,” said Ezra Cohen, MD, Chief Medical ...
ByTempus
Caresyntax, the leading vendor of enterprise-scale data-driven surgical intelligence solutions to make surgery safer and smarter, today announced its highlights and achievements of 2023, as the company has continued its strong growth journey. Dennis Kogan, co-founder, and CEO: “Caresyntax celebrated its 10-year anniversary in 2023 and accelerated our journey of innovation and expansion ...
The launch of Caresyntax CDaaS follows the recently announced addition of CQInsights (CQI) and appointment of Dr. Bruce Ramshaw as Chief Medical Informatics Officer (CMIO) for Caresyntax. The integration of the CQI solution into the Caresyntax platform enables a stack of technologies and capabilities with new digital workflows that can acquire curated data and ...
Synaptive Medical, a global medical device and technology company solving surgical, imaging and data challenges, is pleased to announce the appointment of Timothy J. Scannell as the new Chair of the Board of Directors, effective June 20, 2023. Mr. Scannell joined Synaptive Medical’s Board of Directors in August 2022, bringing a wealth of ...
“We are still in the early stages of working with these peptides, and there are likely other health benefits that we have not yet been able to tap into,” said Andrew Franklyn-Miller, PhD, chief medical and innovation officer for Nuritas. A berry with benefits Mibelle AG Biochemistry, which offers supplements for skin vitality and hair growth, entered ...
JUNE Medical is delighted to announce a new agreement with a major US hospital group to supply the award-winning Galaxy II® self-retaining surgical retractors to over 1,600 hospitals in the US, commencing April 15, 2023. This game-changing device radically improves the safety and ease of surgical retraction for both patients and medical staff; its ergonomic design transforms the way in which ...
“Even when blood glucose levels and blood pressure are well-controlled, the risk of kidney disease progression and cardiovascular events remains high in patients with chronic kidney disease and type 2 diabetes,” said Dr. Michael Devoy, Chief Medical Officer of Bayer’s Pharmaceuticals Division. “Kerendia addresses a key cause of disease ...
ByBayer AG
Cummings joins the ONY Biotech team as Chief Medical Officer, and the founder of the company and former Chief Medical Officer, Dr. ...
“There is a significant need in the field of neurodegenerative diseases for novel treatment strategies, specifically solutions that are cost-effective and globally scalable,” said Bill Erhardt, M.D., Chief Medical Officer of Oligomerix. “We have demonstrated preclinical safety and efficacy of our oral, small molecule program through well ...
” “These exciting results provides further confidence in the Oligomerix approach as we prepare to enter clinical testing next year,” said Bill Erhardt, M.D., Chief Medical Officer of Oligomerix. “By year end, Oligomerix will complete all necessary IND enabling studies and we will submit our IND to FDA during 1Q22. ...
“Ninety percent of drug candidates fail to make it to the marketplace because of failed clinical development strategies,” said Dr. Michael Castro, M.D., Chief Medical Officer at Cellworks Group. “Low efficacy is often not because the drug fails to hit its target, but is more often a consequence of a molecularly naïve approach to a ...
Utilizing the growing medical technologies to help prevent further bone mass loss can make the management of osteoporosis a little easier. ...
Amily Zhang, Antengene's Chief Medical Officer. “The mechanism of action of ATG-037 in inhibiting adenosine-generating CD73 is expected to reverse an immunosuppressed tumor microenvironment, thereby creating potential additive benefit with multiple immuno-oncological approaches. ...
Walid Abi-Saab has decided to retire from the company as Chief Medical Officer and member of the Executive Committee, effective 31 December 2022. ...
Iterative Health, a pioneer in precision-medicine technologies for gastroenterology, announced today that it has partnered with Gastro Health, a national leading medical group specializing in digestive and liver health, to bring its AI Recruitment (AIR) technology to Gastro Health’s practices. ...
“We conducted this study to further analyze our hypothesis that changing the pharmacokinetic profile of lenalidomide may result in clinically superior pharmacodynamic outcomes,” said Jamie Oliver, the Company’s Chief Medical Officer. “We are encouraged by these results and believe STAR-LLD has the potential to provide a significant benefit ...
Michael Castro, MD, Neuro-oncologist, Medical Oncologist at Beverly Hills Cancer Center; Chief Medical Officer at Cellworks, Group Inc. and Co-Principal Investigator of the study. ...
Having clarified the Phase 3 study designs, the Company is now expanding its partnering activities on XF-73 Nasal with the aim of securing a deal in 2023. Dr Yuri Martina, Chief Medical Officer of Destiny Pharma, said: “Having finalized our Phase 3 strategy for our primary indication of SSI prevention, we are ready for the next steps in executing our ...